Tritonix.ai

News / Taiwan / economic_daily

TaiGen's Influenza Drug Pixavir Included in China's National Reimbursement List

Health Technology · Pharmaceuticals: Major · economic_daily · 2026-11-17

4157

TaiGen Biotechnology's flu drug Pixavir marboxil has been added to China's national insurance formulary, with sales expected to ramp up starting in 2027.

What Happened

Inclusion in National Formulary: TaiGen Biotechnology announced that its self-developed influenza antiviral drug, Pixavir marboxil, has been officially included in China's National Reimbursement Drug List. The policy will take effect on January 1, 2027, marking a significant milestone in the drug's commercialization within the Chinese market.

Partnership and Commercialization: Marketed as "Yi Li Kang" in China, the drug is managed by partner Joincare Pharmaceutical Group, which oversees local development, manufacturing, and commercialization. Joincare's successful application for reimbursement status is expected to facilitate the drug's entry into public hospital prescription systems.

Market Penetration Strategy: TaiGen Chairman Huang Kuo-lung noted that overcoming the self-pay barrier will significantly improve accessibility and market penetration. By leveraging the national insurance payment system, the drug is expected to see increased adoption during peak influenza seasons as patient costs are reduced.

Financial Impact: Following the implementation of the reimbursement policy, TaiGen expects to benefit from future sales royalties. This development is set to provide a meaningful boost to the company's growth momentum starting in 2027, validating its strategy of international drug development and licensing.

Read original

More in Health Technology

Latest in Taiwan